News Releases Keyword Search Year None2023202220212020201920182017201620152014 Mar 01, 2023 Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results Feb 09, 2023 Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease Jan 03, 2023 Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None2023202220212020201920182017201620152014 Mar 01, 2023 Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results Feb 09, 2023 Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease Jan 03, 2023 Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
